Under the agreement Janssen will have broad access to Proteros' drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and fully integrated structure-based lead discovery programs to identify small molecule inhibitors. This is a consolidation of the services Proteros has provided over the past eight years in support of Janssen discovery research efforts in the USA and Europe.  

 

Dr. Torsten Neuefeind, CEO of Proteros noted that "it is an important milestone for Proteros that the work performed by our scientists to support Janssen global discovery research is recognized as being of such high value that is has developed into this strategic collaboration. Proteros looks forward to contributing innovations and high quality science that makes a positive impact on Janssen's research success."  

Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery, with an aim to accelerate and improve protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros boasts that it complements its clients' internal capabilities with external expertise and access to flexible resources. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.